⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
LM11A-31
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-12 — LM11A-31 Safety and Tolerability in Aging People Living With HIV and Neurocognitive Impairment: [human-rct — provisional trial-status classification, not outcome evidence] A 48-week early-phase human trial is evaluating LM11A-31 safety, tolerability, and biomarker effects in older adults living with HIV and mild neurocognitive impairment; the supplied finding reports no results and does not specify randomization. [human-rct] (novelty: 3)
Open questions
Related
Contributing findings
LM11A-31 Safety and Tolerability in Aging People Living With HIV and Neurocognitive Impairment
12-nov-2026
novelty 3
per-area 3
strengthens